Century Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$1.12 | $0.05 | -$0.51 |
| Q2 2024 | 3 | -$0.99 | $0.05 | -$0.45 |
| Q3 2024 | 1 | -$0.98 | $0.05 | -$0.45 |
| Q4 2024 | 3 | -$0.43 | -$0.40 | -$0.42 |
| Q1 2025 | 3 | -$0.44 | -$0.42 | -$0.43 |
| Q2 2025 | 2 | -$0.97 | $0.05 | -$0.45 |
| Q3 2025 | 2 | -$0.96 | $0.05 | -$0.44 |
| Q4 2025 | 2 | -$1.01 | $0.05 | -$0.46 |
| Q1 2026 | 1 | -$1.02 | $0.05 | -$0.47 |
| Q2 2026 | 1 | -$1.03 | $0.05 | -$0.47 |
| Q3 2026 | 1 | -$1.04 | $0.05 | -$0.48 |
| Q4 2026 | 1 | -$1.07 | $0.05 | -$0.49 |
Century Therapeutics, Inc. Earnings Date And Information
Century Therapeutics, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.37 earnings per share for the quarter, topping analysts' consensus estimates of $-0.46 by $0.09. The company had revenue of 791,000 for the quarter and had revenue of 2.24 M for the year. Century Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.3 diluted earnings per share) and currently has a price-to-earnings ratio of -0.79. Century Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based on prior year's report dates.
Century Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$0.46 | -$0.37 | 0.09 | $440,000 | $791,000 |
| 08/08/2024 | Q2 2024 | -$0.50 | -$0.38 | 0.12 | $430,000 | $771,000 |
| 05/09/2024 | Q1 2024 | -$0.50 | -$0.45 | 0.05 | $855,000 | |
| 03/14/2024 | Q4 2023 | -$0.56 | -$0.66 | -0.1 | $268,000 | |
| 11/09/2023 | Q3 2023 | -$0.53 | -$0.55 | -0.02 | $1.32 M | $148,000 |
| 08/09/2023 | Q2 2023 | -$0.54 | -$0.56 | -0.02 | $1.14 M | $99,000 |
| 05/11/2023 | Q1 2023 | -$0.53 | -$0.53 | 0 | $1.72 M | |
| 03/16/2023 | Q4 2022 | -$0.60 | -$0.54 | 0.06 | $521,000 | |
| 11/10/2022 | Q3 2022 | -$0.59 | -$0.53 | 0.06 | $1.08 M | $2.22 M |
| 08/11/2022 | Q2 2022 | -$0.50 | -$0.54 | -0.04 | $1.34 M | $1.40 M |
| 05/16/2022 | Q1 2022 | -$0.45 | -$0.66 | -0.21 | $1.06 M | |
| 03/17/2022 | Q4 2021 | -$0.46 | -$0.52 | -0.06 | $0 | |
| 11/10/2021 | Q3 2021 | -$0.40 | -$0.48 | -0.08 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.42 | -$0.43 | -0.01 | $0 | |
| 03/30/2021 | Q1 2021 | -$0.33 | $0 | |||
| 12/30/2020 | Q4 2020 | -$0.37 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.31 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.37 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.23 | $0 |
Century Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Century Therapeutics, Inc.'s earnings date?
Century Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates.
-
Did Century Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Century Therapeutics, Inc. (:IPSC) reported $-0.37 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.46 by $0.09.
-
How can I listen to Century Therapeutics, Inc.'s earnings conference call?
The conference call for Century Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Century Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Century Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Century Therapeutics, Inc. generate each year?
Century Therapeutics, Inc. (:IPSC) has a recorded annual revenue of $2.24 M.
-
How much profit does Century Therapeutics, Inc. generate each year?
Century Therapeutics, Inc. (:IPSC) has a recorded net income of $2.24 M. Century Therapeutics, Inc. has generated $-2.3 earnings per share over the last four quarters.
-
What is Century Therapeutics, Inc.'s price-to-earnings ratio?
Century Therapeutics, Inc. (:IPSC) has a price-to-earnings ratio of -0.79 and price/earnings-to-growth ratio is -0.03.
